Indegene, a scientific-knowledge partner to pharma-biotech and healthcare majors globally, is aggressively moving to explore the market further with its range of proprietary products, medical education, marketing, training, business intelligence and analytics services.
It is looking at inorganic growth in the US and EU to enhance its competitive position. The company may chart organic growth strategy for the emerging markets.
For over a decade, the company has been collaborating with 18 of the top 20 companies in 30 countries including US and Europe, serving clients in multiple markets and local affiliates. Now it is keen to augment its presence in emerging markets and Asia-Pacific region.
As part of its growth plans it is strengthening its team from the current 275 to 400 by the end of March 2011. These will include medical doctors, PhDs, pharma marketing experts who will need to interface with global customers.
The effort is also to further bolster sales from its proprietary platforms: 'Phynyx' a multi-channel solution for e-marketing and doctor engagement, 'Optimax' a versatile patient support compliance platform, 'Medengage' a virtual management of advisory boards and 'Trialpedia' an advanced clinical trial analytics and benchmarking solution.
"Our scientific expertise, scale of operations, offshore delivery model and global footprint has helped us garner over 80 per cent revenues from global markets with the balance coming from the Indian market", Manish Gupta, director, Indegene told Pharmabiz.
The company's competence spans from medical writing, marketing, e-marketing programs, publication writing, training, eLearning, medical information management, medical fact checking and review of all marketing-training materials, patient compliance, adherence programme management and update data bases.
With regulated markets of US and Europe looking at economies-of-scale at highest quality deliverables, Indegene utilizes Intellectual Property to develop innovative platforms and solutions for 18 out of the 20 top pharma-healthcare companies for multiple markets. In addition, it is also an offshore partner for strategic commercialization and marketing to 4 of the top 10 pharmaceutical companies, he added.
"We are the most-sought after at this phase as companies in the US and European Union are experimenting with alternative channels of growth to access economies-of-scale in scale-up process. Indegene is uniquely poised to deliver substantial cost benefit as well as value-addition to clients by successfully collaborating with teams in global markets through a scalable hybrid delivery model to offer significant cost benefits", said Gupta.